Expanded Access to ABBV-8E12

Lead sponsor

AbbVie

Asset

Tilavonemab

Listed sites

Recruiting sites

Enrollment

Study population

Frontotemporal dementia

Key I/E criterion

•Age ≥40

Primary endpoint

Identifiers

Registered as

Org study IDC19-364

Other grantC19-921AbbVie

NCT IDNCT03744546

Timeline

Milestones

Study first posted2018-11-16actual

Last update posted2019-08-20actual

Assets

Drug assets

Tilavonemab

Study populations

Who this study enrolls

Frontotemporal dementia

Eligibility

Who can enroll

Minimum age40 Years

Healthy volunteersNot accepted

Endpoints (0)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

No endpoints recorded for this trial.

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 21, 2026

Endpoint classificationDelfa ADRD endpoint taxonomy

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 21, 2026 snapshot.